High Serum Concentration of Interleukine-6 and Rank-ligand as Risk Factors for Osteoporosis in Estrogen Deficiency Post-menopausal Women

Osteoporosis in post-menopausal women is not merely due to deficient estrogenhormone production. The development of osteoporosis is due to increased boneresorption by osteoclasts. The osteoclast\u27s number and activity is controlled by activatingfactors such as IL-6 and RANK-L. The objective of this study was to determine that highIL-6 and RANK-L serum concentrations are risks for osteoporosis in estrogen deficientpost-menopausal women. The serum concentration of ß-CrossLaps (CTx) was measuredto determine bone resorption rate. This is an observational analytical study using case andcontrol design conducted at Sanglah General Hospital of Denpasar. The sample size wascalculated using the paired case-control study formula. There were 41 osteoporotic and41 non-osteoporotic (control) estrogen deficient post-menopausal women involved in thestudy.Data were analyzed by using the t-paired and McNemar tests. Mean serumconcentration of IL-6 among the osteoporotic women was significantly higher ascompared to that of the controls (3.47±1.75 pg/ml vs 2.51±1.13 pg/ml, p = 0.001). Meanserum concentration of RANK-L among the osteoporotic women was also significantlyhigher as compared to that of the controls (320.66±122.44ng/ml vs 249.94±82.41 ng/ml,p = 0.002). To qualify as risk factors for osteoporosis, the cut-off point for IL-6 was 2.17pg/ml (OR = 4, CI 95%: 1.23-14.24; p = 0.032); the cut-off point for RANK-L was275.165 ng/ml (OR = 8, CI 95%: 1.84-34.79; p = 0.001). Analysis of both high serumconcentration of IL-6 and RANK-L was associated with an odd ratio of 9 (CI 95%: 4,27-18,96, p=0,000). CTx concentration in the osteoporotic women was significantly higherthan in the controls (0.60±0.22ng/ml vs 0.46±0.16ng/ml, p = 0.004).We found that the high IL-6 and RANK-L serum concentrations were risk factorsin estrogen deficient post-menopausal women. CTx being a marker for osteoclastic boneresorption activity, increased in concentration higher in osteoporotic than in nonosteoporoticwomen. The high serum concentrations of IL-6 and RANK-L could be usedas predictors for osteoporosis in estrogen deficient post-menopausal women

HIGH SERUM CONCENTRATION OF INTERLEUKINE-6 AND RANK-LIGAND AS RISK FACTORS FOR OSTEOPOROSIS IN ESTROGEN DEFICIENCY POST-MENOPAUSAL WOMEN

Osteoporosis in post-menopausal women is not merely due to deficient estrogenhormone production. The development of osteoporosis is due to increased boneresorption by osteoclasts. The osteoclast’s number and activity is controlled by activatingfactors such as IL-6 and RANK-L. The objective of this study was to determine that highIL-6 and RANK-L serum concentrations are risks for osteoporosis in estrogen deficientpost-menopausal women. The serum concentration of ß-CrossLaps (CTx) was measuredto determine bone resorption rate. This is an observational analytical study using case andcontrol design conducted at Sanglah General Hospital of Denpasar. The sample size wascalculated using the paired case-control study formula. There were 41 osteoporotic and41 non-osteoporotic (control) estrogen deficient post-menopausal women involved in thestudy.Data were analyzed by using the t-paired and McNemar tests. Mean serumconcentration of IL-6 among the osteoporotic women was significantly higher ascompared to that of the controls (3.47±1.75 pg/ml vs 2.51±1.13 pg/ml, p = 0.001). Meanserum concentration of RANK-L among the osteoporotic women was also significantlyhigher as compared to that of the controls (320.66±122.44ng/ml vs 249.94±82.41 ng/ml,p = 0.002). To qualify as risk factors for osteoporosis, the cut-off point for IL-6 was 2.17pg/ml (OR = 4, CI 95%: 1.23-14.24; p = 0.032); the cut-off point for RANK-L was275.165 ng/ml (OR = 8, CI 95%: 1.84-34.79; p = 0.001). Analysis of both high serumconcentration of IL-6 and RANK-L was associated with an odd ratio of 9 (CI 95%: 4,27-18,96, p=0,000). CTx concentration in the osteoporotic women was significantly higherthan in the controls (0.60±0.22ng/ml vs 0.46±0.16ng/ml, p = 0.004).We found that the high IL-6 and RANK-L serum concentrations were risk factorsin estrogen deficient post-menopausal women. CTx being a marker for osteoclastic boneresorption activity, increased in concentration higher in osteoporotic than in nonosteoporoticwomen. The high serum concentrations of IL-6 and RANK-L could be usedas predictors for osteoporosis in estrogen deficient post-menopausal women

Deteksi Dini Osteoporosis Pada Wanita Pra Dan Pasca Menopause

The objective of this study is to find out available means to detect early decreasing bone mass which can also be used to detennine the type of osteoporosis. By finding applicable means enabling to detect early process of bone loss as well as to determine the type of osteoporosis, it would be possible to do early prevention of any side l!tfects of osteoporosis. The population in this study is based on the observational study. The subject of this study are healthy women not in pregmancy or lactation, between age 20-79 years. The study conducted into two phases, mainly: A. Preliminary study, aiming to find the normal level of bone mass, the pattern of bone loss, and the prevalance of osteoporosis among women between age 20 - 79 years. 13. Final study, aiming to predict the process of bone lost and to detennine the variation of primary osteoporosis among women between age 30 - 69 y.ears. The statistical analysis used in this study as follows. lnterence analysis tor the preliminary study, and t - test of means of honnonal, and biochemical bone markers among the categorical group, correlation analysis between bone mass and biochemical bone markers, and regression analysis to determine if bone turnover can be used as predictor of bone mass for the fmal study

Tumor Tulang Primer

Bagian yang terpenting dari Orthopaedi Pathology adalah tumor. Incidence tumor tulang primer tidak dapat dibandingkan dengan carcinoma dari Mamma, Cervic, Paru & organ-2 digestive yang lain ( 1 ) Disamping itu pengetahuan mengenai tumor tulang primer, mutlak perlu dike - tahui mengingat diagnosa bandingnya adalah semua hal yang menyebabkan keru-sakan (Destruksi) tulang, pula diagnosa harus dibuat sedini mungkin terutama pada yang ganas ( 1.8.11. ) Diagnosa tumor tulang primer atas dasar keadaan klinis, radiologis & Histopa- thologis , tetapi yang paling penting adalah Histopathologis ( 1.2. 3. 6.8. 9.11.15) Sediaan untuk pemeriksaan Histopathologis bisa didapatkan dari incisional ataupun excisional biopsy, kalau memungkinkan sebaiknya dilakukan frozen section. Terutama untuk tumor-2 yang diperkirakan ganas, dengan alasan me-ngurangi penyebaran tumor, oleh karena dikerjakan diantara 2 tourniquet dan pula mempercepat diagnosa ( 1.8.). Pengelolaan tumor tulang primer sebaiknya dikerjakan oleh suatu team yang terdiri dari : Ahli Bedah ( Orthopaedi ) : Ahli Radiology / Radio Therapy , Ahli Pathology, Fisiotherapist dan kalau perlu malahan juga Immunotherapis ( 1. 7. 8. 11. 13.). Tumor tulang primer adalah Tumor Tulang yang berasal dari sel - sel yang membentuk tulang, karena sel-sel tersebut bermacam-macam jenisnya maka tumor tulang primer terdiri dari lebih satu jenis tumor. ( 1.8.) Untuk membicarakan tumor tulang primer diperlukan klasifikasi. Dalam usaha membuat klasifikasi ini ternyata banyak pengarang membuat me-nurut seleranya masing-masing, oleh karena itulah banyak didapatkan klasifi - kasi yang bermacam-macam ( 1.8.11. ). ,Tumor-turaor tulang primer yang diamati selama periode 1978 1980 di Bagi-an Bedah R.S. Dr. Soetomo, dibuat klasifikasi menurut Lichtenstein, yaitu berdasarkan pemeriksaan Cytologynya

Impact of bone marker feedback on adherence to once monthly ibandronate for osteoporosis among Asian postmenopausal women

peer reviewedAim: This study assesses the impact of serum carboxy-terminal collagen crosslinks (CTX) bone marker feedback (BMF) on adherence to ibandronate treatment in Asian postmenopausal women with osteoporosis. Methods: This was a 12-month (6-monthly phased), randomized, prospective, open-label, multi-center study conducted in 596 (of 628 enrolled) postmenopausal women with osteoporosis (£ 85 years old) who were naı¨ve, lapsed, or current bisphosphonate users. Patients were randomized into two arms: serum CTX BMF at 3 months versus no-BMF. Once-monthly 150 mg ibandronate tablet was administered for 12 months and adherence to therapy was assessed at 6 and 12 months. In addition, patient satisfaction and safety of ibandronate treatment were also assessed. Results: Serum CTX BMF at 3 months showed no impact on adherence. The proportions of adherent patients were comparable in the BMF versus no-BMF arms (92.6% vs. 96.0%, P = 0.16); overall, serum CTX levels were similar for adherent and non-adherent patients. However, BMF patients felt more informed about their osteoporosis (P < 0.001) and more satisfied (P < 0.01) than no-BMF patients. Conclusions: The Asian postmenopausal osteoporosis patients in this study had a high adherence rate to once-monthly ibandronate therapy. Use of serum CTX BMF had no further impact on increasing adherence, but increased treatment satisfaction.the BonAdAsia study grou